170 related articles for article (PubMed ID: 36387068)
1. Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis.
Gong T; Huang Q; Tang F; Wang Y; Li Z; Luo Y; Min L; Zhou Y; Tu C
Front Oncol; 2022; 12():1031787. PubMed ID: 36387068
[TBL] [Abstract][Full Text] [Related]
2. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
3. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
[No Abstract] [Full Text] [Related]
4. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
5. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
[No Abstract] [Full Text] [Related]
7. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
8. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
9. Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer.
Cui Q; Mao Y; Wu D; Hu Y; Ma D; Zhang L; Liu H
Front Oncol; 2022; 12():952494. PubMed ID: 36387189
[TBL] [Abstract][Full Text] [Related]
10. A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients.
Yang M; Liu X; Zhang C; Liao F; Li Z; Luo X; Sun Y; Chen C
Cancer Manag Res; 2019; 11():8869-8876. PubMed ID: 31632146
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
14. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial.
Li DD; Tao ZH; Wang BY; Wang LP; Cao J; Hu XC; Zhang J
NPJ Breast Cancer; 2022 Sep; 8(1):110. PubMed ID: 36127351
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.
Zhang R; Chen Y; Liu X; Gui X; Zhu A; Jiang H; Shao B; Liang X; Yan Y; Zhang J; Song G; Li H
Front Oncol; 2023; 13():1076469. PubMed ID: 37397355
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study.
Tian Z; Gu Z; Wang X; Liu Z; Yao W; Wang J; Zhang P; Cai Q; Ge H
Medicine (Baltimore); 2019 May; 98(19):e15650. PubMed ID: 31083265
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.
Yanwei L; Feng H; Ren P; Yue J; Zhang W; Tang P; Shang X; Pang Q; Liu D; Chen C; Pan Z; Tao YZ
Oncologist; 2020 Oct; 25(10):e1464-e1472. PubMed ID: 32342599
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: A single-center observational study.
Zheng K; Xu M; Wang L; Yu X
Medicine (Baltimore); 2018 Aug; 97(31):e11734. PubMed ID: 30075583
[TBL] [Abstract][Full Text] [Related]
20. Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients.
Pan D; Liu D; Liang L; Shen T; Shi C; Qin H
Front Oncol; 2022; 12():863392. PubMed ID: 35664730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
